CTLA4 and neoplasm: We used human CTLA-4 gene knock in mice (164) to show that tumor rejection mediated by Ipilimumab, an FDA-approved anti-CTLA-4 antibody, can be abrogated by an antibody that blocks interaction between IgG Fc and FcgRII and III (162).